Last updated on November 2018

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Subjects With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy


Brief description of study

Primary Objective:

To demonstrate the non-inferiority of sotagliflozin dose 1 compared to glimepiride on HbA1c (glycosylated A1c) reduction in patients with T2D (type 2 diabetes) who have inadequate glycemic control with metformin.

Secondary Objectives:

To demonstrate the superiority of sotagliflozin dose 1 compared to glimepiride on change in body weight, SBP (systolic blood pressure) in patients with baseline SBP 130 mmHg, SBP in all patients, and proportion of patients with at least 1 documented symptomatic hypoglycemic event (70 mg/dL).

  • To demonstrate the superiority of sotagliflozin dose 1 compared to placebo on change in HbA1c, body weight, SBP in patients with baseline SBP 130 mmHg, SBP in all patients.
  • To demonstrate the superiority of sotagliflozin dose 2 compared to placebo on change in HbA1c.
  • To demonstrate the non-inferiority of sotagliflozin dose 2 compared to glimepiride on change in HbA1c.
  • To demonstrate the superiority of sotagliflozin dose 1 compared to glimepiride on change in HbA1c.
  • To evaluate the safety and tolerability of sotagliflozin compared to glimepiride and placebo.

Detailed Study Description

Up to 58 weeks, including a Screening Period consisting of a Screening phase of up to 2 weeks, a 2-week single-blind placebo Run-in phase, a 52-week double-blind Treatment Period, and a 2-week post-treatment Follow-up period to collect safety information.

Clinical Study Identifier: NCT03332771

Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 8407106
Pomona, CA United States
4.23miles

Trial Transparency email recommended (Toll ...

Investigational Site Number 8407034
Upland, CA United States
6.52miles

Trial Transparency email recommended (Toll ...

Investigational Site Number 8407096
Rancho Cucamonga, CA United States
8.51miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.